FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2544443493> ?p ?o ?g. }

• W2544443493 endingPage "27" @default.
• W2544443493 startingPage "17" @default.
• W2544443493 abstract "Prostate cancer (PCa) represents an important target for chemoprevention given its prolonged natural history and high prevalence. Epidemiologic and laboratory data suggest that vitamin D and genistein (soy isoflavone) may decrease PCa progression. The effect of vitamin D on prostate epithelial cell proliferation and differentiation is well documented and genistein may augment this affect through inhibition of the CYP24 enzyme, which is responsible for intracellular vitamin D metabolism. In addition, both genistein and vitamin D inhibit the intraprostatic synthesis of prostaglandin E2, an important mediator of inflammation. The objectives of this prospective multicenter trial were to compare prostate tissue calcitriol levels and down-stream related biomarkers in men with localized prostate cancer randomized to receive cholecalciferol and genistein versus placebo cholecalciferol and placebo genistein during the pre-prostatectomy period.Men undergoing radical prostatectomy were randomly assigned to one of two treatment groups: (1) cholecalciferol (vitamin D3) 200,000 IU as one dose at study entry plus genistein (G-2535), 600 mg daily or (2) placebo cholecalciferol day 1 and placebo genistein PO daily for 21-28 days prior to radical prostatectomy. Serum and tissue analyses were performed and side-effects recorded.A total of 15 patients were enrolled, 8 in the placebo arm and 7 in the vitamin D3 + genistein (VD + G) arm. All patients were compliant and completed the study. No significant differences in side effect profiles were noted. Utilization of the VD + G trended toward increased calcitriol serum concentrations when compared to placebo (0.104 ± 0.2 vs. 0.0013 ± 0.08; p=0.08); however, prostate tissue levels did not increase. Calcidiol levels did not change (p=0.5). Immunohistochemistry for marker analyses using VECTRA automated quantitation revealed a increase in AR expression (p=0.04) and a trend toward increased TUNEL staining (p=0.1) in prostate cancer tissues in men randomized to receive VD + G compared to placebo.In this first study testing the combination of a single, large dose of cholecalciferol and daily genistein, the agents were well tolerated. While an increase in AR expression suggesting differentiation was observed, it is difficult to draw firm conclusions regarding the bioactivity of the combination given the sample size." @default.
• W2544443493 created "2016-11-04" @default.
• W2544443493 creator A5008376174 @default.
• W2544443493 creator A5014356411 @default.
• W2544443493 creator A5016030632 @default.
• W2544443493 creator A5016348831 @default.
• W2544443493 creator A5051405334 @default.
• W2544443493 creator A5055461813 @default.
• W2544443493 creator A5055870934 @default.
• W2544443493 creator A5064387672 @default.
• W2544443493 creator A5070840030 @default.
• W2544443493 creator A5073338534 @default.
• W2544443493 creator A5088979830 @default.
• W2544443493 date "2016-01-01" @default.
• W2544443493 modified "2023-09-26" @default.
• W2544443493 title "Phase IIa, randomized placebo-controlled trial of single high dose cholecalciferol (vitamin D3) and daily Genistein (G-2535) versus double placebo in men with early stage prostate cancer undergoing prostatectomy." @default.
• W2544443493 cites W1179258730 @default.
• W2544443493 cites W1488048258 @default.
• W2544443493 cites W1877307747 @default.
• W2544443493 cites W1952900486 @default.
• W2544443493 cites W1966825446 @default.
• W2544443493 cites W1970661863 @default.
• W2544443493 cites W1986655758 @default.
• W2544443493 cites W1990249046 @default.
• W2544443493 cites W2006437539 @default.
• W2544443493 cites W2007982969 @default.
• W2544443493 cites W2021463266 @default.
• W2544443493 cites W2029000583 @default.
• W2544443493 cites W2031082758 @default.
• W2544443493 cites W2033538744 @default.
• W2544443493 cites W2047290588 @default.
• W2544443493 cites W2050239312 @default.
• W2544443493 cites W2050400980 @default.
• W2544443493 cites W2053610974 @default.
• W2544443493 cites W2055393332 @default.
• W2544443493 cites W2072000804 @default.
• W2544443493 cites W2073126167 @default.
• W2544443493 cites W2074134383 @default.
• W2544443493 cites W2078348418 @default.
• W2544443493 cites W2078792235 @default.
• W2544443493 cites W2079972311 @default.
• W2544443493 cites W2090432146 @default.
• W2544443493 cites W2095612244 @default.
• W2544443493 cites W2099338693 @default.
• W2544443493 cites W2099875690 @default.
• W2544443493 cites W2101995865 @default.
• W2544443493 cites W2103914520 @default.
• W2544443493 cites W2105346319 @default.
• W2544443493 cites W2105555511 @default.
• W2544443493 cites W2110615083 @default.
• W2544443493 cites W2117584790 @default.
• W2544443493 cites W2133060411 @default.
• W2544443493 cites W2136848797 @default.
• W2544443493 cites W2138260922 @default.
• W2544443493 cites W2143183201 @default.
• W2544443493 cites W2143507112 @default.
• W2544443493 cites W2143750753 @default.
• W2544443493 cites W2158649734 @default.
• W2544443493 cites W2169547723 @default.
• W2544443493 cites W2169884964 @default.
• W2544443493 cites W2275785652 @default.
• W2544443493 cites W2279928617 @default.
• W2544443493 cites W2394951667 @default.
• W2544443493 cites W3135529189 @default.
• W2544443493 cites W84889176 @default.
• W2544443493 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5069272" @default.
• W2544443493 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27766277" @default.
• W2544443493 hasPublicationYear "2016" @default.
• W2544443493 type Work @default.
• W2544443493 sameAs 2544443493 @default.
• W2544443493 citedByCount "5" @default.
• W2544443493 countsByYear W25444434932017 @default.
• W2544443493 countsByYear W25444434932018 @default.
• W2544443493 countsByYear W25444434932019 @default.
• W2544443493 countsByYear W25444434932022 @default.
• W2544443493 crossrefType "journal-article" @default.
• W2544443493 hasAuthorship W2544443493A5008376174 @default.
• W2544443493 hasAuthorship W2544443493A5014356411 @default.
• W2544443493 hasAuthorship W2544443493A5016030632 @default.
• W2544443493 hasAuthorship W2544443493A5016348831 @default.
• W2544443493 hasAuthorship W2544443493A5051405334 @default.
• W2544443493 hasAuthorship W2544443493A5055461813 @default.
• W2544443493 hasAuthorship W2544443493A5055870934 @default.
• W2544443493 hasAuthorship W2544443493A5064387672 @default.
• W2544443493 hasAuthorship W2544443493A5070840030 @default.
• W2544443493 hasAuthorship W2544443493A5073338534 @default.
• W2544443493 hasAuthorship W2544443493A5088979830 @default.
• W2544443493 hasConcept C121608353 @default.
• W2544443493 hasConcept C124490489 @default.
• W2544443493 hasConcept C126322002 @default.
• W2544443493 hasConcept C126894567 @default.
• W2544443493 hasConcept C134018914 @default.
• W2544443493 hasConcept C142724271 @default.
• W2544443493 hasConcept C179639408 @default.
• W2544443493 hasConcept C204787440 @default.
• W2544443493 hasConcept C27081682 @default.
• W2544443493 hasConcept C2776079296 @default.
• W2544443493 hasConcept C2776235491 @default.

• next